. Author manuscript; available in PMC: 2014 May 1.

Published in final edited form as: Osteoporos Int. 2012 Sep 21;24(5):10.1007/s00198-012-2143-2. doi: 10.1007/s00198-012-2143-2

Table 2.

Baseline clinical characteristics of randomized participants

Characteristic	POWIR (N=35) Mean (SD)	FLEX (N=36) Mean (SD)	p value^*
Age (years)	46.5 (5.0)	46.4 (4.9)	0.90
Comorbidity index	1.9 (1.6)	2.1 (1.6)	0.66
Body mass index (kg/m²)	27.0 (5.4)	25.8 (4.6)	0.32
Spine T-score	−0.5 (1.1)	−0.4 (1.0)	0.86
Femoral neck T-score	−0.4 (0.9)	−0.5 (0.9)	0.46
FSH (IU)	79.5 (45.0)	62.9 (33.9)	0.09
Estradiol (pg/ml)	15.0 (20.1)	35.0 (79.3)	0.16
Time since diagnosis (months)	30.1 (18.3)	30.1 (15.5)	0.99
Time since menopause (months)	24.1 (17.4)	26.1 (15.4)	0.61
Stage I (%)	22.9 %	33.3 %	0.41^**
Stage II (%)	65.7 %	50.0 %
Stage IIIa (%)	11.4 %	16.7 %
Received radiation therapy (%)	62.9 %	61.1 %	0.88
Currently taking AI (%)	40.0 %	30.6 %	0.70^**
Currently taking SERM (%)	37.1 %	44.4 %

Data presented as mean (SD) for continuous data or percentage of sample for categorical data

AI aromatase inhibitor; SERM selective estrogen receptor modulator

p value from unpaired t test for continuous data and from chi-squares test for categorical data;

^**

p value for differences in the distribution of cancer stage (I, II, or IIIa) or adjuvant hormone therapy (none, AI, and SERM) between study groups